Targeting Bacterial Cell Division with Benzodioxane–Benzamide FtsZ Inhibitors as a Novel Strategy to Fight Gram-Positive Ovococcal Pathogens
Authors:
- Berenice FurlanBFBerenice Furlan
- Marta Sobrinos-SanguinoMSMarta Sobrinos-Sanguino
- Marcella SammartinoMSMarcella Sammartino
- Begoña MonterrosoBMBegoña Monterroso
- Silvia ZorrillaSZSilvia Zorrilla
- Alessia LanziniALAlessia Lanzini
- Lorenzo SuigoLSLorenzo Suigo
- Ermanno ValotiEVErmanno Valoti
- Orietta MassiddaOMOrietta Massidda
- Valentina StranieroVSValentina Straniero
Open Access
- 16 January 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (2) , 714
Abstract
The widespread emergence of antimicrobial resistance (AMR) is a serious threat to global public health and among Gram-positive cocci, Streptococcus pneumoniae constitutes a priority in the list of AMR-threatening pathogens. To counteract this fundamental problem, the bacterial cell division cycle and the crucial proteins involved in this process emerged as novel attractive targets. FtsZ is an essential cell division protein, and FtsZ inhibitors, especially the benzamide derivatives, have been exploited in the last decade. In this work, we identified, for the first time, some benzodioxane–benzamide inhibitors capable of targeting FtsZ in Streptococcus pneumoniae, in addition to their previously demonstrated activity against other bacteria. These promising benzamides, with minimal inhibitory concentrations (MICs) ranging from 25 to 80 µg/mL, demonstrated bactericidal activity against S. pneumoniae. This was evidenced by their ability to dramatically affect growth and viability, further supported by the morphological changes observed through microscopy. Moreover, the compounds were characterized in vitro, combining turbidity measurements and confocal imaging, and significant alteration of a GTP-induced FtsZ assembly was found, in line with our previous data from other microorganisms.Keywords
Funding Information
- MICIU/AEI/10.13039/501100011033 (PID2019-104544GB-I00, PID2022-136951NB-I00, PTA2020-018219-I)
- MICIU/AEI/10.13039/501100011033 (PID2019-104544GB-I00, PID2022-136951NB-I00, PTA2020-018219-I)
- MICIU/AEI/10.13039/501100011033 (PID2019-104544GB-I00, PID2022-136951NB-I00, PTA2020-018219-I)
This publication has 49 references indexed in Scilit:
- Identification of ethyl-6-bromo-2((phenylthio)methyl)imidazo[1,2-a]pyridine-3-carboxylate as a narrow spectrum inhibitor of Streptococcus pneumoniae and its FtsZEuropean Journal of Medicinal Chemistry, 2024
- Benzodioxane-benzamides as promising inhibitors of Escherichia coli FtsZInternational Journal of Biological Macromolecules, 2023
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Benzodioxane‐Benzamides as Antibacterial Agents: Computational and SAR Studies to Evaluate the Influence of the 7‐Substitution in FtsZ InteractionChemMedChem, 2019
- 2,6‐Difluorobenzamide Inhibitors of Bacterial Cell Division Protein FtsZ: Design, Synthesis, and Structure–Activity RelationshipsChemMedChem, 2017
- 3-(Benzodioxan-2-ylmethoxy)-2,6-difluorobenzamides bearing hydrophobic substituents at the 7-position of the benzodioxane nucleus potently inhibit methicillin-resistant Sa and Mtb cell divisionEuropean Journal of Medicinal Chemistry, 2016
- Benzodioxane–benzamides as new bacterial cell division inhibitorsEuropean Journal of Medicinal Chemistry, 2015
- Bacterial cytokinesis: From Z ring to divisomeCytoskeleton, 2012
- Development of a homogeneous fluorescence anisotropy assay to monitor and measure FtsZ assembly in solutionAnalytical Biochemistry, 2011
- Advances in understanding E. coli cell fissionCurrent Opinion in Microbiology, 2010